Celgene International Sárl Release: Premier Cooperative Group in Adult Lymphoma Research Chooses REVLIMID(R) for Major Study in Disease’s Largest Patient Population

BOUDRY, Switzerland & PARIS--(BUSINESS WIRE)--Celgene International Sàrl (Nasdaq: CELG) and the Groupe d’Etude des Lymphomes de l’Adulte (GELA) today announced the initiation of an international randomized, double-blind, controlled Phase III study to evaluate the therapeutic potential of REVLIMID (lenalidomide) as a maintenance therapy for elderly, high-risk patients with diffuse large B-cell lymphoma (DLBCL) who have responded to standard first line Rituximab, Cyclophosphamide, Doxorubicin, Oncovin and Prednisolone (R-CHOP). Currently, there is no approved therapy proven to maintain remission after induction with R-CHOP therapy in patients with DLBCL. GELA is the leading Cooperative Group in the world for studying the treatment of adult lymphoma patients, and its work has helped establish the standard of care in the treatment of DLBCL, as well as other lymphoma histologies.